Comparative Pharmacology
Head-to-head clinical analysis: MORPHABOND ER versus OPANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MORPHABOND ER versus OPANA.
MORPHABOND ER vs OPANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine is a full opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins. Activation of mu receptors leads to G-protein-coupled inhibition of adenylyl cyclase, decreased cAMP production, closure of voltage-gated calcium channels, and opening of potassium channels. This results in reduced neuronal excitability, inhibition of neurotransmitter release (e.g., substance P, glutamate), and modulation of pain signaling pathways, producing analgesia, euphoria, and sedation.
Mu-opioid receptor agonist; produces analgesia by binding to opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
15-30 mg orally every 12 hours, titrated to effect; maximum 60 mg per dose or 120 mg daily.
5-20 mg orally every 4-6 hours as needed for pain; extended-release tablets: 5 mg orally every 12 hours, titrated up to 20 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in adults, allowing once-daily dosing for MORPHABOND ER. In hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is 11-16 hours (mean 14 hours) in adults; prolonged in hepatic impairment (up to 30 hours) and elderly.
Approximately 90% excreted renally as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), with ~10% excreted unchanged. Fecal elimination accounts for <10%.
Primarily renal (approximately 90% as conjugated metabolites, 10% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic